Innate Pharma (NASDAQ:IPHA) Trading Up 1.9% - Time to Buy?

Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report)'s stock price rose 1.9% during mid-day trading on Friday . The company traded as high as $2.16 and last traded at $2.13. Approximately 10,035 shares traded hands during trading, a decline of 97% from the average daily volume of 325,721 shares. The stock had previously closed at $2.09.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $11.50 target price on shares of Innate Pharma in a research report on Thursday, February 6th.

Innate Pharma Trading Down 2.9 %

The stock's 50-day moving average is $1.94 and its two-hundred day moving average is $1.96.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.